WCI

RI Related News

비회원이 작성한 글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.

List Next Prev
게시글 내용
Framatome to support Global Morpho Pharma’s high-capacity technology development for Lutetium-177 separation
2024/01/08

Framatome and Global Morpho Pharma announced a service agreement for the development of a high-capacity technology for the purification of medical radioisotope non-carrier-added (n.c.a.) Lutetium-177 (Lu-177). This will contribute to aligning production capacity with the increasing demand for this radioisotope and will serve innovations and developments in cancer treatments.

 

The global demand for n.c.a. Lu-177 is expected to increase 15-fold by 2030 to reach a number of 300,000 patients, that are predicted to be treated. Initiatives across the manufacturing chain are needed to align the production with this growing demand. Global Morpho Pharma’s technology will enable a significant increase in target processing capacity and contribute to securing the supply of n.c.a Lu-177.

 

To read more please visit:

Framatome to support Global Morpho Pharma’s high-capacity technology development for Lutetium-177 separation

Source: Framatome